OCT-1, ABCB1, and ABCG2 Expression in Imatinib-Resistant Chronic Myeloid Leukemia Treated with Dasatinib or Nilotinib. - Wikidata - wikimedia - TriplyDB

OCT-1, ABCB1, and ABCG2 Expression in Imatinib-Resistant Chronic Myeloid Leukemia Treated with Dasatinib or Nilotinib.

OCT-1, ABCB1, and ABCG2 Expression in Imatinib-Resistant Chronic Myeloid Leukemia Treated with Dasatinib or Nilotinib.

http://www.wikidata.org/entity/Q34774289

about

New trends for overcoming ABCG2/BCRP-mediated resistance to cancer therapies A Cell-Based Assay for Measuring Endogenous BcrAbl Kinase Activity and Inhibitor Resistance OCT1 and imatinib transport in CML: is it clinically relevant?Current trends in molecular diagnostics of chronic myeloid leukemia.Effect of bosutinib on the absorption of dabigatran etexilate mesylate, a P-glycoprotein substrate, in healthy subjects.The hOCT1 and ABCB1 polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia.Molecular Response to Imatinib and Its Correlation with mRNA Expression Levels of Imatinib Influx Transporter (OCT1) in Indian Chronic Myeloid Leukemia Patients The clinical significance of ABCB1 overexpression in predicting outcome of CML patients undergoing first-line imatinib treatment.Trough concentration and ABCG2 polymorphism are better to predict imatinib response in chronic myeloid leukemia: a meta-analysis.Imatinib Affects the Expression of SLC22A1 in a Non-Linear Concentration-Dependent Manner Within 24 Hours.Overexpression of miR-202 re-sensitizes imatinib resistant chronic myeloid leukemia cells through targeting Hexokinase 2 (HK2).

P2860

Q28067499-456A2AD2-0EA2-4A95-BBE3-243A2A640A82 Q28553892-F3334262-C988-43BA-8968-035A57FA006B Q38540022-C1B472D5-6D44-4B91-8F36-40E9FBB443D3 Q38787015-DD39F777-D4EE-4BA5-8723-F4EE06361397 Q39310587-BA77939C-B87A-4190-B7D7-E7F7918227F7 Q45790127-D223DF7A-9940-46EC-B0E8-D3006C7AC4B9 Q47117554-67F339D7-1BA9-4F18-AF11-6E227D704693 Q50784710-992FCF3D-FCF1-4AB1-9503-4827CDEC9327 Q51251518-5C468CAA-FCDB-483A-8DD2-E7E469176B68 Q52641813-6D7D74F7-E5B9-4FC4-8DE8-9D7FD3409192 Q52646158-99207542-D85D-464E-B938-55DA9A25F3E7

P2860

OCT-1, ABCB1, and ABCG2 Expression in Imatinib-Resistant Chronic Myeloid Leukemia Treated with Dasatinib or Nilotinib.

http://www.wikidata.org/entity/Q34774289

description

2014 nî lūn-bûn

@nan

2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

OCT-1, ABCB1, and ABCG2 Expres ...... d with Dasatinib or Nilotinib.

@ast

OCT-1, ABCB1, and ABCG2 Expres ...... d with Dasatinib or Nilotinib.

@en

OCT-1, ABCB1, and ABCG2 Expres ...... d with Dasatinib or Nilotinib.

@nl

type

label

OCT-1, ABCB1, and ABCG2 Expres ...... d with Dasatinib or Nilotinib.

@ast

OCT-1, ABCB1, and ABCG2 Expres ...... d with Dasatinib or Nilotinib.

@en

OCT-1, ABCB1, and ABCG2 Expres ...... d with Dasatinib or Nilotinib.

@nl

prefLabel

OCT-1, ABCB1, and ABCG2 Expres ...... d with Dasatinib or Nilotinib.

@ast

OCT-1, ABCB1, and ABCG2 Expres ...... d with Dasatinib or Nilotinib.

@en

OCT-1, ABCB1, and ABCG2 Expres ...... d with Dasatinib or Nilotinib.

@nl

P1433

Q34774289-D6004786-CE17-4846-B1F9-F571D5A6AD44

P1476

Q34774289-39581688-A3D1-4401-8216-6A9ECD5F3E15

P2093

Q34774289-2C845D30-05C9-42A5-8B0D-31EB9A9B05D2

Q34774289-33B96BF4-D8FD-4D48-A391-33AED44BE115

Q34774289-5E1A6C7A-FD6F-4489-9A1E-FB7221C65D52

Q34774289-690415AC-E346-46C5-9D67-BE82AE96C7EE

Q34774289-78C659C7-EEEC-4474-98EC-B88D9FCB7F5F

Q34774289-C50083F7-1F0F-4712-AA3E-2D28F82EB600

Q34774289-EF4D50FC-FABD-47C6-891D-1C56A38BC1BA

Q34774289-F33BC427-0CD3-489D-B0C7-FC5115BF2C83

P2860

Q34774289-09D5EEC5-80B9-4D66-9FEB-9B5A578D1899

Q34774289-0D5D2DF9-330E-439B-8937-ED11E2EEAC99

Q34774289-0E760BCD-8A9C-4E35-BB35-C874F7194FAA

Q34774289-1F79B91F-7A17-4C75-BEB1-D664CCFC10B6

Q34774289-245B85BC-8AC4-43B8-A1E5-80E0BE5F2D1F

Q34774289-31B7FEB2-C5A0-4F9F-8984-032AE920C6B9

Q34774289-34183EE3-4459-4DFF-A85E-07A4D5AB3DC6

Q34774289-358D30B1-C63C-4140-ADF1-F66274540471

Q34774289-384D58B4-CC2F-41EB-B84A-ADD9EB36E142

Q34774289-3C497347-9243-4200-AE49-40539C9105FC

P304

Q34774289-18AFE8AB-71F5-4AC0-9D79-5DE24BD4C6FC

P31

Q34774289-87CF5BEA-3728-4147-9D7C-E6B870AC448E

P356

Q34774289-A403E6D0-B24C-4C87-BDCD-EB4BF07A62D6

P433

Q34774289-79B0AD23-C68C-4272-9820-224BB2BDF341

P478

Q34774289-038D17CA-4B6C-4D58-B6F8-8C5E83A70838

P577

Q34774289-25CDB0EE-507A-40CD-9557-A658497FAAE6

P5875

Q34774289-B67B0AE7-CAFF-4C9A-A63E-10857B8AC27A

P698

Q34774289-8ADD6972-39E9-4786-8C92-D89C514AA042

P921

Q34774289-1BF8D910-F7F6-4B0C-861C-ECEE2DC63BD9

Q34774289-877B2A75-816F-4010-8242-A1E746A0F5EF

P932

Q34774289-CCA1E8A4-36CF-4B47-9FA7-5B66AEE91398

P356

CMJ.2014.50.3.102

P1433

Chonnam Medical Journal

P1476

OCT-1, ABCB1, and ABCG2 Expres ...... d with Dasatinib or Nilotinib.

@en

P2093

Deok-Hwan Yang

http://www.w3.org/2001/XMLSchema#string

Hyeoung-Joon Kim

http://www.w3.org/2001/XMLSchema#string

Jae-Sook Ahn

http://www.w3.org/2001/XMLSchema#string

Je-Jung Lee

http://www.w3.org/2001/XMLSchema#string

Myung-Geun Shin

http://www.w3.org/2001/XMLSchema#string

Seung-Shin Lee

http://www.w3.org/2001/XMLSchema#string

Sung-Hoon Jeong

http://www.w3.org/2001/XMLSchema#string

Yeo-Kyeoung Kim

http://www.w3.org/2001/XMLSchema#string

P2860

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump.

Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib.

Drug transporters and imatinib treatment: implications for clinical practice.

Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy.

Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failed.

Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors.

ATP-binding-cassette transporters in hematopoietic stem cells and their utility as therapeutical targets in acute and chronic myeloid leukemia.

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance.

P304

102-111

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4068/CMJ.2014.50.3.102

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

50

http://www.w3.org/2001/XMLSchema#string

P577

2014-12-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

270659563

http://www.w3.org/2001/XMLSchema#string

P698

25568846

http://www.w3.org/2001/XMLSchema#string

P921

chronic myeloid leukemia

P932

4276791

http://www.w3.org/2001/XMLSchema#string